Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.74+1.76 (+5.87%)
Close on Nov 18, 2026Market cap $373.06MP/E –Yield –
Surrozen revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Surrozen's revenue for the twelve months ending Jun 30, 2026 was $11.51M, down 8.8% year over year. For fiscal 2025 it was $3.48M, down 67.4% from the year before. The highest annual figure on record is $12.50M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.48M | -67.4% |
| FY2024 | Dec 31, 2024 | $10.66M | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $12.50M | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.00M | +408.6% |
| Q1 FY2026 | Mar 31, 2026 | $5.00M | +408.6% |
| Q4 FY2025 | Dec 31, 2025 | $528.00K | -19.4% |
| Q3 FY2025 | Sep 30, 2025 | $983.00K | -90.2% |
| Q2 FY2025 | Jun 30, 2025 | $983.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $983.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $655.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $10.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
See a number that looks wrong?